Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
By I. Edwards HealthDay Reporter
WEDNESDAY, May 7, 2025 — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.
The division oversees vaccines and biologic medicines, including gene therapies, CNN reported.
Prasad is a hematologist-oncologist, a specialist in treating cancers of the blood. He has been a vocal critic of the U.S. government's response to the COVID-19 pandemic. He has questioned school closures, mask mandates and COVID booster shots.
He takes over from Dr. Peter Marks, who led the division for 13 years and played a major role in the COVID vaccine rollout. Marks resigned in March, writing in a letter that U.S. health secretary Robert F. Kennedy Jr. did not value science and transparency.
FDA Commissioner Dr. Marty Makary praised Prasad’s background, saying he has a "long and distinguished history in medicine" and highlighted his oncology research, according to CNN.
Prasad’s appointment comes as the FDA plans to require future vaccines to be tested through placebo-controlled trials.
Public health officials are also reconsidering recommendations for COVID vaccines for children — recommendations Prasad has questioned, because kids face lower risks from the virus than older people and those with weakened immune systems.
Amid news of his appointment, biotech stocks fell more than 5%. Sarepta Therapeutics, which makes a gene therapy for Duchenne muscular dystrophy, saw its stock drop nearly 25%.
Prasad had criticized the FDA’s approval of that treatment, Elevidys, saying its benefits were uncertain.
In a social media post earlier this year, Prasad wrote, “The FDA did nothing to speed gene therapy, other than talk about how they will use uncontrolled endpoints. But we want to speed effective gene therapy, not ineffective gene therapy. The FDA had no solution for that.”
Sources
- CNN, May 6, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
8 Babies Born Using New IVF Technique to Prevent Rare Genetic Diseases
FRIDAY, July 18, 2025 — A new IVF technique helped eight babies in the U.K. avoid serious inherited diseases, and scientists are calling it a breakthrough. All eight...
Hispanic People Have Unexplained Higher Risk For Nerve Disorder
FRIDAY, July 18, 2025 — Hispanic people are more likely to develop peripheral neuropathy than white people, and it’s not clear why, a new study has found. Hispanic...
Living Near Polluted Missouri Creek as a Child Tied to Later Cancer Risk
THURSDAY, July 17, 2025 — Folks who grew up near a polluted Missouri creek during the 1940s through 1960s may have higher odds for cancer now, new research shows. The study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.